Pharmaceuticals News and Research

RSS

WaferGen and University of Pittsburgh to collaborate on SmartChip

WaferGen Biosystems, Inc. has announced that it has established a research collaboration with the University of Pittsburgh Medical School to have it serve as the alpha test site for WaferGen's SmartChip Real-Time PCR System.

14 Nov 2007

Telomerase enzyme structure provides significant new target for anti-cancer therapies

Inappropriate activation of a single enzyme, telomerase, is associated with the uncontrollable proliferation of cells seen in as many as 90 percent of all of human cancers. Since the mid-1990s, when telomerase was first identified in human tumors, scientists have eyed the enzyme as an ideal target for developing broadly effective anti-cancer drugs.

14 Nov 2007

Hope on the horizon for hereditary angioedema sufferers

Although there is currently no treatment approved by the Federal Drug Administration (FDA) for acute attacks of hereditary angioedema (HAE) - a genetic disease causing swelling of extremities, face and internal organs that can be life-threatening - hope is on the horizon according to a team of experts presenting the latest research at the Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Dallas.

14 Nov 2007

New drug may restore memory with Alzheimer's disease

A 2006 study by MetLife found that adults over age 55 fear Alzheimer's disease more than cancer, and with good reason. Alzheimer's creeps up on patients and their families, robbing more than half of all Americans over age 85 of their memory and ability to care for themselves.

14 Nov 2007

Foamix issued cosmetic and pharmaceutical foam patent approvals

Foamix Ltd., a leading developer of topical foam products for dermatology, gynecology and skin-care, has been awarded a New Zealand patent and four South African patents related to the Company's proprietary foam technology.

14 Nov 2007

Brazilian experience of AIDS cocktails

AIDS continues to be a staggering global public health problem. The World Health Organization estimates that two million people in developing countries receive treatment known as HAART (highly active antiretroviral therapy), more commonly known as “AIDS cocktails.”

13 Nov 2007

Lexicon files investigational NDA for LX2931 in rheumatoid arthritis

Lexicon Pharmaceuticals, Inc. has announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for LX2931, an oral drug candidate for rheumatoid arthritis and other autoimmune conditions.

13 Nov 2007

Could a new vaccine be the key to stopping Alzheimer's disease?

A new study from the Oklahoma Medical Research Foundation (OMRF) shows that immunization could offer a way to blunt or even prevent the deadly, memory-robbing disease.

13 Nov 2007

High fat diets throw body clock out of sync

The researchers from the Northwestern University and Evanston Northwestern Healthcare in Illinois, suggest that overeating alters the core mechanism of the body clock and disrupts the timing of internal signals such as appetite control.

7 Nov 2007

New liver model for drug tests

In the early stages of drug development, a drug’s effect is tested in animal experiments.

6 Nov 2007

Printed human organs!

Each year, pharmaceutical companies invest millions of dollars to test drugs, many of which will never reach the market because of side effects found only during human clinical trials.

6 Nov 2007

Fat cells release a protein that aids insulin secretion from pancreatic beta cells

The body's fat cells help the pancreas do its job of secreting insulin, according to research at Washington University School of Medicine in St. Louis.

6 Nov 2007

Bavarian Nordic updates on vaccine project pipeline

In a business update, Danish-based biopharmaceutical company Bavarian Nordic, reported a number of developments in its vaccine project pipeline.

6 Nov 2007

Microcarrier patent to be auctioned

Sedum Laboratories, Inc., formerly of Mansfield, Mass., is auctioning its U.S. Patent #6,645,525 titled "Ionically Formulated Biomolecule Microcarriers."

6 Nov 2007

Brain chemical anandamide work as antidepressant

American and Italian researchers have found that boosting the amounts of a marijuana-like brain transmitter called anandamide produces antidepressant effects in test rats.

6 Nov 2007

Immtech receives $5.1 million to tackle trypanosomiasis and leishmania

Immtech Pharmaceuticals, Inc. has announced that it has received $5.1 million from a scientific consortium led by the University of North Carolina at Chapel Hill (UNC), which received funds from The Bill & Melinda Gates Foundation, to develop drugs for fighting African sleeping sickness (trypanosomiasis) and leishmania.

6 Nov 2007

Bayer Pharmaceuticals agrees to a marketing suspension of Trasylol

The U.S. Food and Drug Administration (FDA) has announced that, at the agency's request, Bayer Pharmaceuticals Corp. has agreed to a marketing suspension of Trasylol, a drug used to control bleeding during heart surgery, pending detailed review of preliminary results from a Canadian study that suggested an increased risk for death.

5 Nov 2007

Fewer U.S. residents purchase prescription drugs from Canada, in part because of Medicare drug benefit

Online drug sales in 2006 from Canadian pharmacies to U.S. consumers dropped about 50%, from $420 million Canadian dollars in 2005 to $211 million Canadian dollars last year, according to data from IMS Health, the Philadelphia Inquirer reports.

5 Nov 2007

United States, Canada and Mexico agree to mutual assistance during public health emergencies

The U.S. Department of Health and Human Services (HHS), the Public Health Agency of Canada, and the Ministry of Health of the United Mexican States today agreed to strengthen cross-border coordination and cooperation in the surveillance, prevention, and control of infectious diseases for the protection of the health, well-being, and quality of life of their peoples.

5 Nov 2007

Hepatitis C virus found to spread directly from cell to cell by-passing antibodies

Scientists looking for an effective treatment for Hepatitis C may face an even bigger task than anticipated. Recent studies looking into how the virus spreads in liver tumour cells have demonstrated that the virus uses two different routes, which may explain why the body's natural occurring antibodies are ineffective at controlling the virus.

5 Nov 2007